Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Jinxin Fertility: Accretive but Slightly Controversial Acquisition of Jinxin WCH

2022 High Conviction: Tail Winds for Jinxin Fertility

Jinxin Fertility: Shenzhen and Yunnan Acquisitions

Jinxin Fertility: Signs of Policy Tailwind and Valuation Dislocation

Jinxin Fertility: Takeaways from Wuhan NDR and Yunnan Acquisition

China: 3rd Child Policy and 3 Beneficiaries

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

Jinxin Fertility Group  / Equity Bottom-Up

<p>Jinxin Fertility reported its 1H2021 results and hosted a conference call. We attended the call which provided a clearer picture of its execution capability and long term growth drivers than ever before. The results reflect a strong recovery post-COVID-19 as well as strong execution in the company's strategies. We continue to like the company and the valuation is undemanding thanks to the recent weakness in the healthcare sector. </p>

Jinxin Fertility reported its 1H2021 results and hosted a conference call. We attended the call which provided a clearer picture of its execution capability and long term growth drivers than ever before. The results reflect a strong recovery post-COVID-19 as well as strong execution in the company's strategies. We continue to like the company and the valuation is undemanding thanks to the recent weakness in the healthcare sector. 

Jinxin Fertility 1H2021: A Clear Picture of the Long Term Potential